Article info
PDFOriginal research
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
- Correspondence to Dr Sinchita Roy-Chowdhuri, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA; sroy2{at}mdanderson.org
Citation
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy
Publication history
- Received April 1, 2021
- Revised April 12, 2021
- Accepted April 13, 2021
- First published May 5, 2021.
Online issue publication
November 15, 2022
Article Versions
- Previous version (15 November 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.